Introduction
MIBG therapy, also known as Iodine-131 MIBG (¹³¹I-MIBG) therapy, is a targeted nuclear medicine treatment used for selected neuroendocrine tumors that actively uptake metaiodobenzylguanidine (MIBG).
It delivers therapeutic radiation directly to tumor cells while minimizing exposure to surrounding healthy tissues.
MIBG is structurally similar to norepinephrine and is selectively absorbed by adrenergic tissue.
This makes MIBG therapy particularly effective for tumors arising from neural crest cells, especially when disease is advanced, metastatic, or not suitable for surgery.
Türkiye is a trusted destination for advanced nuclear medicine therapies, offering experienced specialists, dedicated treatment units, and integrated endocrine and oncology care.
Averia Health supports international patients through ethical, structured, and fully coordinated MIBG therapy focused on safety, precision, and long-term care continuity.
Why Choose Türkiye for MIBG Therapy
Türkiye is internationally recognized for advanced neuroendocrine tumor treatment because of:
- Experienced nuclear medicine physicians and oncologists
- Availability of therapeutic ¹³¹I-MIBG in specialized centers
- Dedicated nuclear medicine therapy and isolation units
- Multidisciplinary care involving endocrinology, oncology, and surgery
- Strict radiation safety and regulatory compliance
- Internationally accredited hospitals
Türkiye combines targeted radionuclide therapy with comprehensive clinical expertise.
Why Choose Averia Health
Averia Health provides structured coordination for MIBG therapy:
- Pre-arrival review of medical history, pathology, and imaging
- Coordination of MIBG diagnostic scan to confirm eligibility
- Referral to experienced nuclear medicine therapy centers
- Multidisciplinary coordination (endocrinology, oncology, nuclear medicine)
- Clear explanation of therapy goals, benefits, and limitations
- Professional interpreter services
- 24/7 patient support during treatment and isolation period
- Post-therapy follow-up and international care coordination
Our approach prioritizes ethical practice, patient safety, and informed decision-making.
Who Is a Candidate for MIBG Therapy
MIBG therapy may be considered for patients with:
- Pheochromocytoma
- Paraganglioma
- Neuroblastoma (selected adult or pediatric cases)
- Metastatic or inoperable neuroendocrine tumors with MIBG uptake
- Disease progression despite conventional treatments
- Adequate bone marrow, kidney, and liver function
Eligibility is confirmed through diagnostic MIBG imaging and specialist evaluation.
Diagnostic Evaluation Before Therapy
Before treatment, patients typically undergo:
- Diagnostic MIBG scan to confirm tumor uptake
- Blood tests to assess bone marrow, kidney, and liver function
- Hormonal and biochemical evaluation (when applicable)
- Review of prior treatments and imaging
- Medication review, including drugs that may interfere with MIBG uptake
- Thyroid blockade preparation
Careful evaluation ensures treatment safety and effectiveness.
MIBG Therapy Procedure
Radiopharmaceutical Administration
¹³¹I-MIBG is administered intravenously in a controlled hospital setting.
Targeted Radiation Delivery
The compound accumulates in MIBG-avid tumor cells and delivers therapeutic radiation.
Isolation and Monitoring
Patients stay in a specialized isolation room to meet radiation safety requirements and are closely monitored.
Treatment is performed by experienced nuclear medicine teams following strict international safety standards.
Treatment Journey in Türkiye
- Pre-Arrival Case Review
Medical records, imaging, and laboratory results are evaluated. - Eligibility Confirmation
Diagnostic MIBG imaging confirms suitability for therapy. - Personalized Treatment Planning
Therapy strategy, precautions, and expectations are discussed clearly. - MIBG Therapy Administration
Treatment is delivered in a dedicated nuclear medicine unit. - Post-Therapy Care & Monitoring
Side effects, vital signs, and laboratory values are monitored. - Follow-Up & Long-Term Care Coordination
Ongoing oncologic and endocrine follow-up is coordinated internationally.
Expected Results & Benefits
- Targeted treatment of MIBG-avid tumors
- Reduction in tumor burden or disease stabilization
- Symptom control in hormone-secreting tumors
- Treatment option when surgery or systemic therapy is limited
- Localized radiation with reduced systemic exposure
Response varies based on tumor type, disease extent, and prior treatments.
Risks & Considerations
MIBG therapy is well established but may involve:
- Temporary bone marrow suppression
- Fatigue
- Nausea or mild gastrointestinal discomfort
- Dry mouth
- Need for radiation safety precautions after treatment
All potential risks and safety measures are explained thoroughly before therapy.
What’s Included in Your Medical Trip
- Pre-therapy consultations and eligibility evaluation
- Diagnostic MIBG scan coordination (if required)
- MIBG therapy administration
- Hospital isolation and monitoring
- Post-therapy care and discharge planning
- Interpreter services
- 24/7 patient support
- International follow-up and oncology coordination
Averia Health ensures ethical, precise, and patient-centered radionuclide therapy care.
Frequently Asked Questions
Is MIBG therapy chemotherapy?
No. It is a targeted radionuclide therapy, not chemotherapy.
Do all neuroendocrine tumors respond to MIBG therapy?
Only tumors that demonstrate MIBG uptake are suitable.
Is thyroid protection required?
Yes. Thyroid blockade is used to prevent iodine uptake by the thyroid gland.
Is the treatment safe?
Yes, when performed in specialized centers with appropriate monitoring.
Can follow-up care continue after returning home?
Yes. International follow-up and coordination are provided.
Ready to Start Your Health Journey?
Access targeted treatment for neuroendocrine tumors with advanced MIBG therapy in Türkiye.
Request a free quote or contact us on WhatsApp to speak with our nuclear medicine therapy coordination team.
